ESC 365 - Two years follow-up of use of SGLT2 inhibitors in HFrEF patients hospitalized for decompensation

ESC2025 Premium Access

Two years follow-up of use of SGLT2 inhibitors in HFrEF patients hospitalized for decompensation

Session: SGLT2 inhibitors in heart failure: prevention and treatment

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Speaker: Associate Professor V. Vintila (Bucharest, RO)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Associate Professor Vlad Damian Vintila

University of Medicine and Pharmacy Carol Davila, Bucharest (Romania)

0 follower

3 more presentations in this session

Right vs. left cardiac function and structure: impact of SGLT2i in acute decompensate heart failure with central sleep apnea

Speaker: Assistant Professor P. Kalaydzhiev (Sofia, BG)

SGLT2 inhibitors improve cardiovascular clinical outcomes in patients undergoing anthracycline chemotherapy: a systematic review and meta-analysis of 13,333 patients.

Speaker: Doctor L. Spadafora (Latina, IT)

THRV-1268, a novel and potent SGK1 inhibitor, improved adverse cardiac remodeling beyond empagliflozin, an SGLT2 inhibitor, by reducing inflammation and fibrosis mechanisms in heart failure.

Speaker: Doctor S. Das (Boston, US)

Access the full session

SGLT2 inhibitors in heart failure: prevention and treatment

Speakers: Associate Professor V. Vintila, Assistant Professor P. Kalaydzhiev, Doctor L. Spadafora, Doctor S. Das

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

bristol-myers-squibb

Explore sponsored resources

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources